Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real‐World Analysis of WHO Pharmacovigilance Data

Clinical Pharmacology and Therapeutics · Published 2026-05-24 · DOI 10.1002/cpt.70326

Free full text

Authors (4)

Natalia Sauer, Piotr Giedziun, Jacek Calik, Anna Wiela‐Hojeńska

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Sauer, N., Giedziun, P., Calik, J., et al. (2026). Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real‐World Analysis of WHO Pharmacovigilance Data. Clinical Pharmacology and Therapeutics. https://doi.org/10.1002/cpt.70326

Related articles

• Cancer Therapy-Related Cutaneous Toxicities: Prognostic Biomarkers, Immunologic Endotypes, and Novel Therapeutic Strategies · Onco · 2026 · Cites or is cited by this article
• Fecal Microbiota Transplantation and Microbiota‐Based Therapeutics in Allogeneic Hematopoietic Stem Cell Transplantation: Current Evidence and Future Directions · Clinical Pharmacology and Therapeutics · 2026 · Same journal
• Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure · Clinical Pharmacology and Therapeutics · 2026 · Same journal
• ASCPT News · Clinical Pharmacology and Therapeutics · 2026 · Same journal
• Reframing the Landscape for Achieving Equitable Pharmacotherapy Health Outcomes: Introducing Pharmacogenequity · Clinical Pharmacology and Therapeutics · 2026 · Same journal
• The Multiple Criteria Qualitative Value‐Based Pricing Framework “ MARIE ” for Novel Cell and Gene Therapy · Clinical Pharmacology and Therapeutics · 2026 · Same journal
• In This Issue · Clinical Pharmacology and Therapeutics · 2026 · Same journal
• From Non‐Cancer Pain to Cancer Survivorship: Applying Opioid Deprescribing Lessons across the Divide · Clinical Pharmacology and Therapeutics · 2026 · Same journal
• Ruxolitinib Pharmacokinetics and Exposure–Toxicity Relationship in Hematologic Malignancies and Immune‐Mediated Diseases: A Prospective Observational Study · Clinical Pharmacology and Therapeutics · 2026 · Same journal
• Early and High‐Dose Glucocorticoid Use and Survival in Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Multicenter Target Trial Emulation · Clinical Pharmacology and Therapeutics · 2026 · Same journal